AS721 - Exploring MGMT constitutional methylation and the MGMT SNP rs16906252 as risk factors for cancer coli, glioblastomas and diffuse large B-cell lymphoma in the WHI study

Investigator Names and Contact Information

Per Lonning (per.lonning@helse-bergen.no)

Introduction/Intent

Here, we will confirm constitutional primary epimutations of MGMT to be a cancer risk factor by evaluating WBC MGMT methylation as risk factor for colorectal cancer, glioblastomas and high-grade lymphomas. Data generated will be used also to model the mechanism(s) of CpG methylation building up across the promotor area, evaluating the different models outlined in Figure 1.

Specific aims.

1. We will assess the HR for right-sided and left-sided colon cancer separately related to WBC MGMT methylation status using a case-control designed study
2. We will assess the HR for glioblastoma multiforme related to WBC MGMT methylation status using a case-control designed study
3. We will assess the HR for high-grade diffuse B-cell lymphomas related to WBC MGMT methylation status using a case-control designed study